| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and/or venous thrombosis associated with antiphospholipid antibodies.
IgG from APS patients and anti-phosphatidylserine/prothrombin antibody (aPS/PT) increased expression of tissue factor (TF) and production of chemokines from endothelial cells (EC). Oxidative stress level was significantly higher in sera of APS patients than in those of healthy subjects. Treatment with oxidative stress led to increase in expression of TF, chemokines, but decrease in the expression of eNOS of EC. The decrease in eNOS leads to a decrease in production of NO, and anti-arteriosclerotic effect by NO might be decreased. It is suggested that the decrease of NO and increase of TF, proinflammatory cytokine and chemokines are cause of thrombosis in APS patients.
In the examination of APS, measurement of anti-cardiolipin antibody (aCL) -IgG is the first test item, followed by measurements of aPS/PT-IgG and aCL-IgM are recommended.
|
